Azilsartan medoxomil (AZL-M), a novel angiotensin receptor blocker, lowers blood pressure (BP) more effectively than olmesartan (OLM) and valsartan (VAL) in patients with hypertension. Post hoc analyses of 3 randomized, placebo- and/or active-controlled trials were conducted to compare the BP-lowering effects of AZL-M, OLM and VAL in black patients with stage 1 and 2 hypertension, using ambulatory (ABPM) and clinic BP monitoring.
Data were pooled from 3 trials that randomized patients to AZL-M (40 and 80 mg), OLM 40 mg, VAL 320 mg, or placebo daily for 6 to 24 weeks. Major endpoints included changes from baseline in 24-hour ambulatory and clinic systolic BP (SBP) and clinic SBP following 6 to 8 weeks.
Most (>90%) black patients were enrolled in the USA. Mean age was 51–53 yr, with 45–58% men. Baseline (BL) 24-h SBP was 145–148 mm Hg; BL clinic SBP was 156–159 mm Hg. Reductions from BL in 24-h mean and clinic SBP were significantly or numerically greater with 40 and 80 mg AZL-M versus each comparator (Table). The proportion of patients achieving goal BP also was higher for subjects receiving AZL-M compared with OLM or VAL (Table). Safety and tolerability measures were similar for AZL-M, active comparators, and placebo.
These data indicate that AZL-M has greater SBP lowering efficacy in black patients with hypertension compared to OLM and VAL at their maximum approved doses.
© 2012 Lippincott Williams & Wilkins, Inc.